Sign In
Buy SRRK
$47.30
-1.70 (-3.46%)
At Close: Jul 31, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscula
Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript
11:33pm, Wednesday, 06'th Aug 2025
Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Akshay K. Vaishnaw - President of R&D, Member of Scientific Advisory Boa
Why Scholar Rock Stock Wilted on Wednesday
05:10pm, Wednesday, 06'th Aug 2025
It didn't take a high-powered academic to figure out why Scholar Rock's (SRRK -5.99%) share price swooned by more than 5% on Wednesday. That morning, the biotech published a quarterly earnings report
Scholar Rock (SRRK) Q2 Loss Widens 63%
04:54pm, Wednesday, 06'th Aug 2025
Scholar Rock (SRRK -6.39%), a late-stage biopharmaceutical company specializing in therapies for serious neuromuscular and rare diseases, released its second quarter 2025 earnings on August 6, 2025. T
Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress
07:00am, Wednesday, 06'th Aug 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 6, 2025-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal m
Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year
04:22pm, Wednesday, 23'rd Jul 2025
On July 18, 2025, Director Jeffrey S. Flier disclosed the sale of 11,136 shares of Scholar Rock (SRRK -0.68%) in an open market transaction.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 18'th Jul 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal
Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users
06:25pm, Tuesday, 24'th Jun 2025
David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in combination with Zepbound helped prevent muscle loss.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (
Why Scholar Rock Shares Are Soaring Today
01:41pm, Wednesday, 18'th Jun 2025
Shares of Scholar Rock Holding (SRRK 14.93%) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly.
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
10:47am, Wednesday, 18'th Jun 2025
Scholar Rock SRRK revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced
Scholar Rock Shares Jump on Positive Results from Weight Loss Trial
07:33am, Wednesday, 18'th Jun 2025
Shares of Scholar Rock climbed after the company disclosed what it called positive results from a Phase 2 study assessing its drug for weight loss.
Scholar Rock's drug helps preserve lean mass in mid-stage trial
07:12am, Wednesday, 18'th Jun 2025
Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (
